First Patient Dosed in Phase 1 Clinical Trial for AMX-883 in Acute Myeloid Leukemia

Amphista Therapeutics has announced that the first patient has been dosed in a Phase 1 clinical trial evaluating its lead candidate, AMX-883, for the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). The trial follows authorization granted by the U.S. Food and Drug Administration in June 2026.

Understanding the BRAMLIE Clinical Trial

The newly initiated trial, designated as the BRAMLIE study, is designed to enroll approximately 54 participants across multiple clinical sites. According to company disclosures, the initial phase of the research will focus on investigating the safety, pharmacokinetics, and preliminary efficacy of AMX-883 administered as a monotherapy. Following the establishment of this monotherapy profile, investigators plan to conduct a multi-center dose-escalation study assessing AMX-883 in combination with standard-of-care treatments for patients with relapsed or refractory AML, as well as those in earlier lines of therapy.

The Mechanism Behind AMX-883

Acute myeloid leukemia is recognized as an aggressive blood cancer responsible for approximately 130,000 deaths worldwide each year. While traditional cytotoxic chemotherapy remains a primary treatment, and novel targeted agents have shown utility, many existing targeted therapies are restricted to specific genetic mutations and benefit only a subset of patients. AMX-883 utilizes a targeted protein degradation mechanism. It is designed as an orally bioavailable small molecule targeting BRD9, a subunit of the chromatin remodeling complex that helps maintain leukemic stemness and blocks myeloid cell differentiation. By recruiting the E3 ligase DCAF16, the agent aims to induce rapid BRD9 degradation while maintaining high selectivity. Preclinical evaluations indicated that AMX-883 demonstrated activity across diverse AML subtypes independent of mutation status, though these findings have yet to be fully validated in human clinical environments.

Expert Insights and Study Outlook

Dr. Eytan Stein, Director of the Program for Drug Development in Leukemia within the Division of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center and Lead Investigator for the trial, noted the ongoing challenges in treating the disease. Dr. Stein pointed out that the five-year survival rate for AML remains low and that emerging resistance to existing standard-of-care treatments underscores the need for novel therapeutic options. Dr. Louise Modis, Chief Executive Officer of Amphista Therapeutics, emphasized that the advancement of the lead asset into clinical evaluation represents a key organizational milestone aimed at exploring new treatment pathways for patients facing significant medical needs.

• Phase 1 BRAMLIE trial aims to enroll about 54 participants.
• Trial evaluates AMX-883 safety, pharmacokinetics, and preliminary efficacy.
• Preclinical data suggested activity across multiple AML mutation subtypes.

Source: News-Medical.net